Perritt Capital Management Inc Has $208,000 Holdings in iCAD, Inc. (NASDAQ:ICAD)

Perritt Capital Management Inc lifted its stake in shares of iCAD, Inc. (NASDAQ:ICAD) by 14.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 159,900 shares of the technology company’s stock after purchasing an additional 19,917 shares during the period. Perritt Capital Management Inc’s holdings in iCAD were worth $208,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of ICAD. First Eagle Investment Management LLC raised its position in iCAD by 3.2% in the 1st quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock worth $1,129,000 after purchasing an additional 22,000 shares during the last quarter. Perritt Capital Management Inc. increased its stake in shares of iCAD by 7.5% in the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after buying an additional 9,717 shares during the period. AMH Equity Ltd acquired a new stake in shares of iCAD in the 1st quarter valued at $207,000. Salem Investment Counselors Inc. bought a new stake in shares of iCAD during the first quarter worth $119,000. Finally, Virtu Financial LLC lifted its stake in shares of iCAD by 55.6% during the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after acquiring an additional 7,604 shares during the period. 24.61% of the stock is owned by institutional investors.

iCAD Price Performance

Shares of NASDAQ:ICAD opened at $1.39 on Thursday. The stock has a market cap of $36.89 million, a price-to-earnings ratio of -11.58 and a beta of 1.51. The company has a 50 day moving average of $1.40 and a 200-day moving average of $1.51. iCAD, Inc. has a one year low of $1.18 and a one year high of $2.65.

iCAD (NASDAQ:ICAD) last announced its quarterly earnings data on Tuesday, August 13th. The technology company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $5.03 million during the quarter. iCAD had a negative net margin of 15.67% and a negative return on equity of 13.59%.

Analysts Set New Price Targets

Separately, StockNews.com upgraded iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, August 22nd.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.